Bladder cancer: Discussions

HCRN GU 16-257, RETAIN

ASCO GU 2023

Bladder preservation strategies - promising data but no…

P. Grivas, M.-O. Grimm, T. Powles, I. Duran, S. Chowdhury, Y. Loriot

CheckMate-257

ASCO GU 2023

Robust DFS benefit, but lack of OS data leaves open…

T. Powles, L.-M. Krabbe, I. Duran, S. Chowdhury, Y. Loriot, P. Grivas

IMvigor130, JAVELIN-Bladder100, TROPHY-U1-cohort3

ASCO GU 2023

New updates on immunocheckpoint inhibitors and ADCs -…

T. Powles, M.-O. Grimm, I. Duran, S. Chowdhury, Y. Loriot, P. Grivas

Bladder cancer - metastasized/localized

HCRN GU 16-257; IMvigor-130; TROPHY-U-01 cohort 2; JAVELIN Bladder 100

ASCO GU 2023

Re-shaping bladder cancer treatment

Ignacio Duran, MD

IMvigor130

ASCO GU 2023

PD-1 as combo in 1st line

Philipp Ivanyi, MD

IMvigor130

ASCO GU 2023

Atezo monotherapy for mUC

Axel S. Merseburger, MD

HCRN GU14-188

ASCO GU 2023

Benefit of neoadjuvant pembro for CE and CI patients

Peter J. Goebell, MD

IMvigor130, CheckMate 274, UNITE

ASCO GU 2023

No change in SoC, but new genomic predictors for EV…

Joaquim Bellmunt, MD

IMvigor 130

ASCO GU 2023

Final OS data show no significant benefit for chemo…

Tom Powles, MD

JAVELIN Bladder

ASCO GU 2023

Update / German Real World Data M1 BC

Philipp Ivanyi, MD

IMvigor130

ASCO GU 2023

IMvigor130: final OS

Axel S. Merseburger, MD

KEYNOTE-057

ASCO GU 2023

Pembro for HR NMIBC

Axel S. Merseburger, MD

IMvigor-130

ASCO GU 2023

No final OS difference - but subgroups may benefit from…

Gil Morgan, MD

Javelin Bladder 100; Trophy-U-01 Cohort 3

ASCO GU 2023

Urothelial cancer highlights from ASCO GU23

Petros Grivas, MD

IMvigor130

ASCO GU 2023

Final overall survival

Marc-Oliver Grimm, MD

Bladder cancer - NIMBC/MIBC

Keynote-057; CheckMate 274

ASCO GU 2023

NMIBC highlights from ASCO GU23

Petros Grivas, MD

Keynote-057

ASCO GU 2023

New data for pembro in HR NIMBC

Joaquim Bellmunt, MD

THOR-2

ASCO GU 2023

Urothelial cancer - hidden gems of the poster session

Tom Powles, MD

CheckMate 274

ASCO GU 2023

3 yrs outcome of Nivo for adjuvant therapy

Marc-Oliver Grimm, MD

CheckMate 274

ASCO GU 2023

Exciting survival data for adjuvant NIVO

Tom Powles, MD

CheckMate-257

ASCO GU 2023

Impressive DFS with adjuvant Nivo in biomarker-positive…

Laura-Maria Krabbe, MD

IMvigor130, CheckMate 274

ASCO GU 2023

The bladder cancer highlights of ASCO GU

Yohann Loriot, MD

CheckMate 274

ASCO GU 2023

Checkpoint inhibition in adjuvant therapy

Philipp Ivanyi, MD

Keynote-057

ASCO GU 2023

Pembrolizumab in HR NIMBC

Tarik Esen, MD

Bladder cancer 100 sec - multi language

HCRN GU 16-257; IMvigor-130; TROPHY-U-01 cohort 2; JAVELIN Bladder 100

ASCO GU 2023

Refinando el tratamiento del cancere vejiga

Ignacio Duran, MD

TRITON3

ASCO GU 2023

PARPi are effective in PCa - which subgroups benefits…

Yohann Loriot, MD

Keynote-057

ASCO GU 2023

BCG yanıtsız yüksek riskli KİOMK tedavisinde…

Tarik Esen, MD

Keynote-057, CheckMate 274, Javelin Bladder 100, Trophy-U-01 Cohort 3

ASCO GU 2023

Επισημάνσεις για τον καρκίνο του ουροθηλίου από την…

Petros Grivas, MD

IMvigor130, CheckMate 274

ASCO GU 2023

The bladder cancer highlights of ASCO GU

Yohann Loriot, MD

ASCO GU 2023

Los aspectos más destacados del ASCO GU 2023 en cáncer…

Joaquim Bellmunt, MD

Prostate cancer: Discussions

TRITON3, MAGNITUDE

ASCO GU 2023

Benefits and risks of precision medicine with PARPi

A. Bjartell, E. Efstathiou, S. Chowdhury, A. S. Merseburger, G. Morgan

ARASENS

ASCO GU 2023

Triplet combination - all-comer therapy or high risk…

S. Chowdhury, A. S. Merseburger, M.-O. Grimm, G. Morgan, A. Bjartell, E. Efstathiou

TALAPRO-2, PROpel

ASCO GU 2023

BRCA mutations in mCRPC - the importance of biomarkers…

A. Bjartell, E. Efstathiou, S. Chowdhury, A. S. Merseburger, G. Morgan

Prostate cancer - advanced/localized

Arasens

ASCO GU 2023

Monotherapy is not any longer standard of care

Neal Shore, MD

ASCO GU 2023

Controversy in ADT roundtable

Neal Shore, MD

FORMULA-509

ASCO GU 2023

Intensification of salvage therapy in high risk…

Peter J. Goebell, MD

ASCO GU 2023

Surgery vs. Radiation for N1 PCa: who wins?

Declan Murphy, MD

ARASENS

ASCO GU 2023

ARASENS - post-hoc subgroup analysis

Axel S. Merseburger, MD

ASCO GU 2023

Normal baseline testosterone level is a strong…

Tarik Esen, MD

ARASENS

ASCO GU 2023

Benefit in all groups

Gil Morgan, MD

ARASENS

ASCO GU 2023

Doublet or all-in: the solution for all patients?

Axel Merseburger, MD; Anders Bjartell,MD

ARASENS

ASCO GU 2023

ARASENS: triple independent of volume and risk

Peter J. Goebell, MD

ARASENS; PEACE-1

ASCO GU 2023

mHSPC - new standard and more insights

Philipp Ivanyi, MD

Formula 509

ASCO GU 2023

Formula 509: Racing to a better straegy for…

Declan Murphy, MD

ASCO GU 2023

New ways to target androgen receptor signaling

Anders Bjartell, MD

NRG/RTOG

ASCO GU 2023

MMAI - a superior prognostic marker for high risk…

Tarik Esen, MD

FORMULA-509

ASCO GU 2023

PARP and testing

Axel S. Merseburger, MD

Prostate cancer - mCRPC

Talapro-2

ASCO GU 2023

Tiebreaker for previous trials

Neal Shore, MD

TALAPRO-2

ASCO GU 2023

TALA in 1st line for all patients with mCRPC

Peter J. Goebell, MD

TALAPRO-2

ASCO GU 2023

PARPi combo: all-comer treatment for mCRPC

Axel S. Merseburger, MD

TRITON3, Talapro2, PROpel

ASCO GU 2023

PARPi combination in mCRPC

Simon Chowdhury, MD

TRITON3

ASCO GU 2023

PARPi study with different design

Anders Bjartell, MD

MAGNITUDE

ASCO GU 2023

PARPi & ARPi with wonderful data

Eleni Efstathiou, MD

TALAPRO-2; PROpel

ASCO GU 2023

PARPi combo approval for all-comers - balancing…

Axel Merseburg, MD; Anders Bartell, MD

TRITON3

ASCO GU 2023

Rucaparib - ready for clinical practice in BRCAmut…

Simon Chowdhury, MD

PROpel

ASCO GU 2023

Propel - final OS

Axel S. Merseburger, MD

Talapro-2

ASCO GU 2023

TALA ENZO with improved PFS in mCRPC

Tarik Esen, MD

TRITON3

ASCO GU 2023

PARPi are effective in PCa - which subgroup benefits…

Yohann Loriot, MD

TRITON3

ASCO GU 2023

Rucaparib: treatment option for biomarker-selected…

Gil Morgan, MD

TRITON3

ASCO GU 2023

Rucaparib - the new player?

Peter J. Goebell, MD

Talapro-2

ASCO GU 2023

Encouraging results for Talazoparib

Gil Morgan, MD

Prostate cancer 100 sec - multi-language

NRG/RTOG

ASCO GU 2023

MMAI- Yüksek riskli prostat kanserinde üstün bir…

Tarik Esen, MD

PACE-A

ASCO GU 2023

Lokalize prostat kanserinde cerrahi ile SBRT…

Tarik Esen, MD

Talapro-2

ASCO GU 2023

TALA ENZA kombinasyonu ile mKDPK olan hastalarda daha…

Tarik Esen, MD

ASCO GU 2023

ASCO GU 2023

Nya vägar att blockera androgenreceptor signalering

Anders Bjartell, MD

ASCO GU 2023

edavi öncesi normal testosteron seviyesi ADT sonrası…

Tarik Esen, MD

TRITON3

ASCO GU 2023

Ny PARP hämmar studie med anna design

Anders Bjartell, MD

Formula 509

ASCO GU 2023

RP sonrası kurtarma RT ile GnRH Analog ABİ APA…

Tarik Esen, MD

ASCO GU 2023

miR371'in orşiektomi sonrası tedavi seçimini…

Tarik Esen, MD

MAGNITUDE

ASCO GU 2023

PARPi & ARPi με υπέροχα δεδομένα

Eleni Efstathiou, MD

Renal cancer - Discussions

COSMIC-313, CaboPoint

ASCO GU 2023

Novel updates on cabozantinib in advance RCC

T. Powels, P. Ivanyi, P. Goebell, H. Hammers, J. Bellmunt, S. K. Pal, S. Chowdhury

ZIRCON

ASCO GU 2023

Theranostics in RCC - usefull tools for ccRCC?!

L.-M. Krabbe, P. Ivanyi, P. J. Goebell, H. Hammers, J. Bellmunt, S. M. Pal, S. Chowdhury

CheckMate_9ER

ASCO GU 2023

Updated data of CheckMate 9ER - impact on real-world…

T. Powels, P. Ivanyi, P. Goebell, H. Hammers, J. Bellmunt, S. K. Pal, S. Chowdhury

Renal cancer - 100 sec

CheckMate 9ER, CaboPoint

ASCO GU 2023

Longer FU confirms significant benefit of Nivo-Cabo,…

Philipp Ivanyi, MD

IMDC

ASCO GU 2023

Outcomes of patients with brain metastases treated with…

Philipp Ivanyi, MD

COSMIC-313; CheckMate_9ER

ASCO GU 2023

New therapy choices for renal cell cancer patients

Tom Powles, MD

CheckMate_9ER

ASCO GU 2023

Reassuring update of CM9ER with longer follow up

Laura-Maria Krabbe, MD

CaboPoint

ASCO GU 2023

First prospective data on 2nd line therapy after IO…

Laura-Maria Krabbe, MD

COSMIC-313

ASCO GU 2023

Hypothesis-generating differences in risks groups

Laura-Maria Krabbe, MD

ZIRCON

ASCO GU 2023

Zircon-PET in RCC

Simon Chowdhury, MD

Varia

ASCO 2023

microbiom & CPI perspectives

Philipp Ivanyi, MD

ASCO GU 2023

High accuracy of miR371 to guide treatment selection…

Tarik Esen, MD

ASCO GU 2023

Refining prediction of stage I seminoma

Ignacio Duran, MD

Varia - multi-language

ASCO GU 2023

Mejorando la estimacion pronostica en Seminoma Estadio…

Ignacio Duran, MD